Skip to content
Research Article Open access CC BY 4.0

Spinal Muscle Atrophy (SMA) in a 5 Years Old Girl from Macedonia: Case Report

Stefan Bittmann, Elisabeth Luchter, Lara Bittmann, Aysel Shirinova

Asian Journal of Pediatric Research · pp. 24–28 · Published 25 Aug 2023

10.9734/ajpr/2023/v13i3274

Abstract

Spinal muscular atrophies are inherited diseases in which nerve cells in the spinal cord and brainstem regress, causing progressive muscle weakness and wasting. There are five main types of spinal muscular atrophy, which are classified according to the severity of muscle weakness and wasting. Depending on the type, one may be confined to a wheelchair, and life expectancy may also be limited. Based on symptoms, the diagnosis can be proven through family history, muscle and nerve function studies, and blood tests to determine the location of the defective gene. Spinal muscular atrophies are usually inherited in an autosomal recessive manner. Thus, for a person to inherit the disease, two genes are necessary, one from each parent. The group of SMA disease in childhood can affect the brain and spinal cord as well as the peripheral nerves. We present a case of a 5 years old girl with spinal muscle atrophy and analyze the different new therapeutical options and future research in the field of spinal muscular atrophy in childhood.

Spinal muscular atrophy (SMA) SMA-child-treatment SMN complexes nerve cells

References (16)

  1. 1 Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy [DOI]
  2. 2 Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy [DOI]
  3. 3 Spinal muscular atrophy [DOI]
  4. 4 Spinal muscular atrophy [DOI]
  5. 5 Advances in Treatment of Spinal Muscular Atrophy – New Phenotypes, New Challenges, New Implications for Care [DOI]
  6. 6 Neurofilament as a potential biomarker for spinal muscular atrophy [DOI]
  7. 7 SMA CARNI-VAL Trial Part I: Double-Blind, Randomized, Placebo-Controlled Trial of L-Carnitine and Valproic Acid in Spinal Muscular Atrophy [DOI]
  8. 8 Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study [DOI]
  9. 9 Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial [DOI]
  10. 10 Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) [DOI]
  11. 11 Risdiplam in types 2 and 3 spinal muscular atrophy: A randomised, placebo‐controlled, dose‐finding trial followed by 24 months of treatment [DOI]
  12. 12 SMA valiant trial: A prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy [DOI]
  13. 13 Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study [DOI]
  14. 14 A Prospective, Crossover Survey Study of Child- and Proxy-Reported Quality of Life According to Spinal Muscular Atrophy Type and Medical Interventions [DOI]
  15. 15 Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial [DOI]
  16. 16 Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza®) [DOI]

Cited by 2

Comparison of machine learning algorithms to identify muscular atrophy and muscular dystrophy

Ganga Bhavani Billa, Venkateswara Rao Peddada · IAES International Journal of Artificial Intelligence (IJ-AI) · 2026

A Floppy Infant with Spinal Muscular Atrophy Type 1: A Case Report

S. Farooqui · Journal of Pediatric Health Sciences · 2026

Article metrics

Real usage data collected on this platform.

52

Page views

0

PDF downloads

16

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.